Otezla significantly improved measures of disease severity in adults with mild-to-moderate plaque psoriasis – Amgen
Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.